Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221097 · ClinicalTrials.gov registry record
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
A clinical trial of Coronavirus and COVID, sponsored by BioFire Defense.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 6
- Study locations
NCT07221097 is a study of Coronavirus and COVID that is actively recruiting participants, run by BioFire Defense. The registered enrollment target is 1,500 participants, above the 1,330-participant average among 20 other Coronavirus trials with a reported enrollment target (13% higher). The trial reports 6 study locations across 6 states.
The verdict
NCT07221097, a study of Coronavirus and COVID, is actively recruiting participants, sponsored by BioFire Defense.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 6
- Study locations
Study Summary
The Biomedical Advanced Research and Development Authority (BARDA) has contracted BioFire Defense (BFDf) to develop the BioFire Emerging Coronavirus (ECoV) Panel, a nucleic acid test capable of detecting coronaviruses from nasopharyngeal swab (NPS) in transport medium. This study aims to evaluate the diagnostic accuracy of the assays comprising the BioFire ECoV Panel. It is hypothesized that the BioFire ECoV Panel assays will be highly sensitive and specific for the detection of the coronaviruses included on the panel.
Conditions Studied
Interventions
- DEVICE Investigational IVD for coronaviruses
Study Locations (6)
California
- Children's Hospital Los Angeles - Los Angeles
District of Columbia
- George Washington University - Washington D.C.
Florida
- Tampa General Hospital - Tampa
Georgia
- Emory University Hospital - Atlanta
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Texas
- University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2026-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221097
The ClinicalTrials.gov registry entry for NCT07221097 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,330-participant average among 20 other Coronavirus trials with a reported enrollment target (13% higher). The listed sponsor is BioFire Defense, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Coronavirus appearing as the primary indexed condition, and to 1 intervention - of which Investigational IVD for coronaviruses is the first listed.
NCT07221097 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT07221097 about?
NCT07221097 is a clinical study titled "Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses". The Biomedical Advanced Research and Development Authority (BARDA) has contracted BioFire Defense (BFDf) to develop the BioFire Emerging Coronavirus (ECoV) Panel, a nucleic acid test capable of detecting coronaviruses from nasopharyngeal swab (NPS) in transport medium. This study aims to evaluate t...
What is the current status of trial NCT07221097?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2025-09-29. Estimated completion is 2026-08.
What conditions does trial NCT07221097 study?
This clinical trial studies the following conditions: Coronavirus, COVID, Respiratory Infection.
What interventions are being tested in trial NCT07221097?
The interventions under investigation include: Investigational IVD for coronaviruses (DEVICE).
Who is sponsoring clinical trial NCT07221097?
This trial is sponsored by BioFire Defense, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221097 being conducted?
This trial has 6 study locations across California, District of Columbia, Florida, Georgia, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronavirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers
RECRUITING
-
A Study to Explore the Role of Gut Flora in COVID-19 Infection
RECRUITING
-
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
RECRUITING
-
COVID-19 Biorepository
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.